^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Eylea (aflibercept intravitreal)

    i
    Other names: BAY86-5321, AVE0005, AVE-0005, VEGF Trap-Eye, AVE 0005, BAY865321, BAY86 5321
    Company:
    Bayer, Chong Kun Dang, Regeneron
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor
    Related drugs:
    14h
    A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity) (clinicaltrials.gov)
    P=N/A, N=75, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    6d
    CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (clinicaltrials.gov)
    P3, N=240, Recruiting, EyePoint Pharmaceuticals, Inc.
    Trial initiation date
    |
    Eylea (aflibercept intravitreal)
    12d
    ALVOEYE-HD: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=256, Recruiting, Alvotech Swiss AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    12d
    Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). (clinicaltrials.gov)
    P3, N=210, Recruiting, King's College Hospital NHS Trust | N=81 --> 210
    Enrollment change • Head-to-Head
    |
    Eylea (aflibercept intravitreal)
    13d
    Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, AiViva BioPharma, Inc.
    New P2 trial
    |
    Eylea (aflibercept intravitreal)
    15d
    THAMES: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P1/2, N=546, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    19d
    Target Trial Emulation Framework for Comparing Early Efficacy of Faricimab and Aflibercept In the Treatment of Patients With Neovascular Age-Related Macular Degeneration With Pigment Epithelium Detachment (ChiCTR2600118980)
    P=N/A, N=97, Zhongshan Hospital, Fudan University; Zhongshan Hospital Fudan University
    New trial
    |
    Eylea (aflibercept intravitreal)
    25d
    A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=187, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    28d
    GLIA-MAC: Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy (clinicaltrials.gov)
    P=N/A, N=60, Completed, Federico II University
    New trial
    |
    Eylea (aflibercept intravitreal)
    1m
    AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema (2025-522231-34-00)
    P2/3, N=172, Not yet recruiting, Alvotech Swiss AG | N=102 --> 172
    Enrollment change
    |
    Eylea (aflibercept intravitreal)
    1m
    A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU) (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Exegenesis Bio | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    1m
    EYP-1901-303: COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (2025-523937-25-00)
    P2/3, N=37, Not yet recruiting, Eyepoint Pharmaceuticals Inc.
    New P2/3 trial
    |
    Eylea (aflibercept intravitreal)